See the DrugPatentWatch profile for stelara
The cost of Stelara can vary significantly based on factors such as dosage, insurance coverage, and pharmacy.
How Much Does a Stelara Prescription Cost Without Insurance?
Without insurance, a Stelara prescription can range from approximately \$6,000 to over \$10,000 for a single dose, depending on the specific formulation and quantity. For instance, a 45 mg injection might cost around \$6,000 to \$8,000, while a 90 mg injection could be in the \$9,000 to \$11,000 range [1].
What Are the Average Out-of-Pocket Costs for Stelara?
With insurance, out-of-pocket costs for Stelara can be substantially lower. Patients may pay anywhere from \$0 to \$250 per month for their prescription, contingent on their insurance plan's formulary, copay, and deductible status. Some patient assistance programs and manufacturer coupons can further reduce these costs, potentially to as low as \$0 per month for eligible individuals [1].
How Does Stelara's Cost Compare to Other Psoriasis Treatments?
Stelara is considered a biologic medication, and its pricing is generally in line with other advanced biologic treatments for conditions like psoriasis, Crohn's disease, and psoriatic arthritis. These medications often have higher price points due to the complex manufacturing processes and significant research and development involved.
When Does Stelara's Patent Protection End?
Stelara's primary patents are set to expire in the coming years, which could pave the way for the introduction of biosimilar versions. Patent expiry dates are crucial for the potential reduction in medication costs as biosimilar competition emerges. Information on specific patent statuses can be found at DrugPatentWatch.com [2].
Are There Patient Assistance Programs for Stelara?
Yes, there are patient assistance programs available that can help eligible patients afford Stelara. These programs, often managed by the manufacturer, can provide financial assistance to reduce copayments or cover the cost of medication for those facing financial hardship.
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com